Remicade Biosimilars Market By Disease Indication (Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI485822 | Publish Date: April 2024 | No. of Pages: 180

Global Remicade Biosimilars Market Overview

Remicade Biosimilars Market size was valued at about USD 15.3 Billion in 2024 and expected to grow at CAGR of 9.30% to extend a value of USD 34.4 Billion by 2034

Biosimilars refers to biological product that are highly similar or identical to already existing FDA approved drug for medication purpose. Remicade (infliximab) is a monoclonal antibody used in the treatment of Crohn’s disease in both adult and pediatric patients. It is also used for treatment of active ulcerative colitis, moderate to severe rheumatoid arthritis in combination with another drug.

Remicade Biosimilars Market - Introduction

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Global Remicade Biosimilars Market Dynamics

Drivers

Restrains

Rising incidence of autoimmune diseases, rheumatoid arthritis

Side effects such as tuberculosis

Accessibility to patients

Stringent regulatory guidelines for development

Faster reaction rate

 

Investment in R & D of biosimilars

 

Regional Insights:

On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

  • North America market is estimated to witness a significantly high revenue share over the forecast period due to rising investment and funding.
  • Systemic and faster drug review process.
  • Stringent  Regulatory Environment
  • Streamlined manufacturing guidelines
  • Asia Pacific market is estimated to witness a fastest revenue share over the forecast period.
  • Rising Health Awareness
  • Rising government support
  • Major investment for Research and Development

Global Remicade Biosimilars Market Segmentation

Dividing this target market into segments:

Remicade biosimilars market is segmented based on Disease Indication, and Region.

Regional Insights:

 Regional Insights - Remicade Biosimilars Market

Disease Indication Insight

On the basis of Disease Indication, the target market is segmented into Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others

Report scope:

Attribute

Details

Market Size 2024

US$ 15.3 Billion

Projected Market Size 2034

US$ 34.4 Billion

CAGR Growth Rate

9.30%

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Million & CAGR from 2024 to 2034

Market Segmentation

By Disease Indication - Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034.

Global Remicade Biosimilars Market Key Players

The key players operating the Remicade biosimilars market includes  Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, and Napp Pharmaceuticals.

Global Remicade Biosimilars Market Key Issues Addressed

Recent Development:

The New Launched Product News,

  • In August 2020, South Korea's Celltrion teamed up with U.K.-based drug delivery firm Intract Pharma to codevelop the world's first tablet version of infliximab, a biosimilar of Johnson & Johnson's immunology blockbuster Remicade. With intravenous and subcutaneous versions of the drug already under its belt, Celltrion hopes the tie-up will further secure its position in the Crohn's disease and ulcerative colitis fields.
  • In December 2019, Avsola (infliximab-axxq), the fourth Remicade Biosimilar was approved by FDA. It is a tumor necrosis factor blocker intended for patients with rheumatoid arthritis, in combination with methotrexate, as well as for patients with Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

Global Remicade Biosimilars Market Company Profile

  • Janssen Biotech, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Alvogen
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer, Inc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Celltrion
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Nippon Kayaku
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Napp Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

FAQs

Segments present in the remicade biosimilars market are by disease indication and by region.

Key players operating in the market of Remicade biosimilarinclude Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, and Napp Pharmaceuticals.

On the basis of disease indication, the Remicade biosimilar has been segmented ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, crohn’s disease, psoriatic arthritis, and plaque psoriasis.

Major investments for research and development of biosimilar production are expected to drive growth of the market

Various pharmaceutical manufactures developed biosimilar to Remicade, which lowered the market share of Remicade due to its high cost and fostered the market of Remicade biosimilars.